DrugPatentWatch Database Preview

Details for Patent: 7,973,040

« Back to Dashboard

Which drugs does patent 7,973,040 protect, and when does it expire?

Patent 7,973,040 protects ZEPATIER and is included in one NDA.

This patent has fifty-nine patent family members in forty-two countries.

Summary for Patent: 7,973,040

Title:	Macrocyclic quinoxaline compounds as HCV NS3 protease inhibitors
Abstract:	The present invention relates to macrocyclic a compound of formula (I) and its use as inhibitors of the hepatitis C virus (HCV) NS3 protease, and in treating or preventing HCV infections. ##STR00001##
Inventor(s):	Harper; Steven (Rome, IT), Summa; Vincenzo (Rome, IT), Liverton; Nigel J. (Harleysville, PA), McCauley; John A. (Maple Glen, PA)
Assignee:	Merck Sharp & Dohme Corp. (Rahway, NJ) Istituto di Ricerche di Biologia Molecolare P. Angeletti SpA (Rome, IT)
Application Number:	12/504,955
Patent Claim Types: see list of patent claims	Compound; Composition; Use;

Drugs Protected by US Patent 7,973,040

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Merck Sharp Dohme	ZEPATIER	elbasvir; grazoprevir	TABLET;ORAL	208261-001	Jan 28, 2016		RX	Yes	Yes			Y	Y

International Family Members for US Patent 7,973,040

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Argentina	072588
Australia	2009274190
Brazil	PI0916235
Canada	2731177